Top

Published in:

01-06-2021 | Coronavirus | Educational Review

2020 update on the renin–angiotensin–aldosterone system in pediatric kidney disease and its interactions with coronavirus

Authors: Ana Cristina Simões e Silva, Katharina Lanza, Vitória Andrade Palmeira, Larissa Braga Costa, Joseph T. Flynn

Published in: Pediatric Nephrology | Issue 6/2021

Abstract

The last decade was crucial for our understanding of the renin–angiotensin–aldosterone system (RAAS) as a two-axis, counter-regulatory system, divided into the classical axis, formed by angiotensin-converting enzyme (ACE), angiotensin II (Ang II), and the angiotensin type 1 receptor (AT1R), and the alternative axis comprising angiotensin-converting enzyme 2 (ACE2), angiotensin-(1-7) (Ang-(1-7)), and the Mas receptor. Breakthrough discoveries also took place, with other RAAS endopeptides being described, including alamandine and angiotensin A. In this review, we characterize the two RAAS axes and the role of their components in pediatric kidney diseases, including childhood hypertension (HTN), pediatric glomerular diseases, congenital abnormalities of the kidney and urinary tract (CAKUT), and chronic kidney disease (CKD). We also present recent findings on potential interactions between the novel coronavirus, SARS-CoV-2, and components of the RAAS, as well as potential implications of coronavirus disease 2019 (COVID-19) for pediatric kidney diseases.

Simões e Silva AC, Teixeira MM (2016) ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis. Pharmacol Res 107:154–162PubMed

Basso N, Terragno NA (2001) History about the discovery of the renin-angiotensin system. Hypertension 38:1246–1249PubMed

Streeten DH, Anderson GH, Freiberg JM, Dalakos TG (1975) Use of an angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension. N Engl J Med 292:657–662PubMed

Simões e Silva AC, Flynn JT (2012) The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol 27:1835–1845PubMed

Santos RA, Ferreira AJ, Simoes e Silva AC (2008) Angiotenisins. In: Bader M (ed) Cardiovascular hormone systems: from molecular mechanisms to novel therapeutics, 1st edn. Wiley, New York, pp 67–100

Santos RA, Brosnihan KB, Chappell MC, Pesquero J, Chernicky CL, Greene LJ, Ferrario CM (1988) Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 11(2 Pt 2):I153–I157PubMed

Schiavone MT, Santos RA, Brosnihan KB, Khosla MC, Ferrario CM (1988) Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A 85:4095–4098PubMedPubMedCentral

Campagnole-Santos MJ, Diz DI, Santos RA, Khosla MC, Brosnihan KB, Ferrario CM (1989) Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Phys 257(1 Pt 2):H324–H329

Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A human homolog of angiotensin-converting enzyme cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:33238–33243PubMed

10.

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87:E1–E9PubMed

11.

Santos RA, Simões e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A 100:8258–8263. https://doi.org/10.1073/pnas.1432869100CrossRefPubMedPubMedCentral

12.

Rodrigues Prestes TR, Rocha NP, Miranda AS, Teixeira AL, Simões e Silva AC (2017) The Anti-inflammatory potential of ACE2/angiotensin-(1-7)/Mas receptor axis: evidence from basic and clinical research. Curr Drug Targets 18:1301–1313PubMed

13.

Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM (2014) Classical renin-angiotensin system in kidney physiology. Compr Physiol 4:1201–1228. https://doi.org/10.1002/cphy.c130040CrossRefPubMedPubMedCentral

14.

Patel S, Rauf A, Khan H, Abu-Izneid T (2017) Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies. Biomed Pharmacother 94:317–325PubMed

15.

Cassis LA, Saye J, Peach MJ (1988) Location and regulation of rat angiotensinogen messenger RNA. Hypertension 11(6 Pt 2):591–596PubMed

16.

Hilgenfeldt U (1988) Half-life of rat angiotensinogen: influence of nephrectomy and lipopolysaccharide stimulation. Mol Cell Endocrinol 56:91–98PubMed

17.

Campbell DJ (2012) Angiotensin II generation in vivo: does it involve enzymes other than renin and angiotensin-converting enzyme? J Renin Angiotensin Aldosterone Syst 13:314–316PubMed

18.

Bock HA, Hermle M, Brunner FP, Thiel G (1992) Pressure dependent modulation of renin release in isolated perfused glomeruli. Kidney Int 41:275–280PubMed

19.

Li XC, Cook JL, Rubera I, Tauc M, Zhang F, Zhuo JL (2011) Intrarenal transfer of an intracellular fluorescent fusion of angiotensin II selectively in proximal tubules increases blood pressure in rats and mice. Am J Physiol Ren Physiol 300:F1076–F1088

20.

Celerier J, Cruz A, Lamande N, Gasc JM, Corvol P (2002) Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension 39:224–228PubMed

21.

Ehlers MR, Fox EA, Strydom DJ, Riordan JF (1989) Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc Natl Acad Sci U S A 86:7741–7745PubMedPubMedCentral

22.

Beldent V, Michaud A, Wei L, Chauvet MT, Corvol P (1993) Proteolytic release of human angiotensin-converting enzyme. Localization of the cleavage site. J Biol Chem 268:26428–26434PubMed

23.

Margolius HS (1996) Kallikreins and kinins. Molecular characteristics and cellular and tissue responses. Diabetes 45(Suppl 1):S14–S19PubMed

24.

Husain A, Graham RM (2000) Drugs, enzymes and receptors of the renin-angiotensin system: celebrating a century of discovery. Harwood Academic Publishers, Sydney

25.

Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE (1991) Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351:233–236PubMed

26.

Konishi H, Kuroda S, Inada Y, Fujisawa Y (1994) Novel subtype of human angiotensin II type 1 receptor: cDNA cloning and expression. Biochem Biophys Res Commun 199:467–474PubMed

27.

Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45:205–251PubMed

28.

De Gasparo M, Catt K, Inagami T, Wright J, Unger T (2000) International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415–472PubMed

29.

Shenoy SK, Lefkowitz RJ (2005) Angiotensin II-stimulated signaling through G proteins and beta-arrestin. Sci STKE 2005(311):cm14PubMed

30.

Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F, Inagami T (1998) Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 273:8890–8896PubMed

31.

Qadri F, Culman J, Veltmar A, Maas K, Rascher W, Unger T (1993) Angiotensin II-induced vasopressin release is mediated through alpha-1 adrenoceptors and angiotensin II AT1 receptors in the supraoptic nucleus. J Pharmacol Exp Ther 267:567–574PubMed

32.

Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM (1998) Converting enzyme determines plasma clearance of angiotensin-(1–7). Hypertension 32:496–502PubMed

33.

Nguyen MTX, Han J, Ralph DL, Veiras LC, McDonough AA (2015) Short-term nonpressor angiotensin II infusion stimulates sodium transporters in proximal tubule and distal nephron. Phys Rep 3:e12496

34.

Yang T, Xu C (2017) Physiology and pathophysiology of the intrarenal renin-angiotensin system: an update. J Am Soc Nephrol 28:1040–1049PubMedPubMedCentral

35.

Forrester SJ, Booz GW, Sigmund CD, Coffman TM, Kawai T, Rizzo V, Scalia R, Eguchi S (2018) Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev 98:1627–1738PubMedPubMedCentral

36.

Takayanagi T, Forrester SJ, Kawai T, Obama T, Tsuji T, Elliott KJ, Nuti E, Rossello A, Kwok HF, Scalia R, Rizzo V, Eguchi S (2016) Vascular ADAM17 as a novel therapeutic target in mediating cardiovascular hypertrophy and perivascular fibrosis induced by angiotensin II. Hypertension 68:949–955PubMed

37.

Dange RB, Agarwal D, Masson GS, Vila J, Wilson B, Nair A, Francis J (2014) Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc Res 103:17–27. https://doi.org/10.1093/cvr/cvu067CrossRefPubMed

38.

Zhang M, Prosser BL, Bamboye MA, Gondim ANS, Santos CX, Martin D, Ghigo A, Perino A, Brewer AC, Ward CW, Hirsch E, Lederer WJ, Shah AM (2015) Contractile function during angiotensin-II activation: increased nox2 activity modulates cardiac calcium handling via phospholamban phosphorylation. J Am Coll Cardiol 66:261–272PubMedPubMedCentral

39.

Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ (2005) Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45:1832–1839PubMed

40.

Lanza K, Perez LG, Costa LB, Cordeiro TM, Palmeira VA, Ribeiro VT, Simões e Silva AC (2020) Covid-19: the renin angiotensin system imbalance hypothesis. Clin Sci 134:1259–1264. https://doi.org/10.1042/CS20200492CrossRef

41.

Kuba K, Imai Y, Penninger JM (2006) Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 6:271–276PubMedPubMedCentral

42.

Sodhi CP, Nguyen J, Yamaguchi Y, Werts AD, Lu P, Ladd MR, Fulton WB, Kovler ML, Wang S, Prindle T Jr, Zhang Y, Lazartigues ED, Holtzman MJ, Alcorn JF, Hackam DJ, Jia H (2019) a dynamic variation of pulmonary ACE2 is required to modulate neutrophilic inflammation in response to pseudomonas aeruginosa lung infection in mice. J Immunol 203:3000–3012PubMed

43.

Wang J, Chen L, Chen B, Meliton A, Liu SQ, Shi Y, Liu T, Deb DK, Solway J, Li YC (2015) Chronic activation of the renin-angiotensin system induces lung fibrosis. Sci Rep 5:15561PubMedPubMedCentral

44.

Rocha NP, Simões e Silva AC, Rodrigues Prestes TR, Feracin V, Machado CA, Ferreira RN, Teixeira AL, Miranda AS (2018) RAS in the central nervous system: potential role in neuropsychiatric disorders. Curr Med Chem 25:3333–3352PubMed

45.

Saavedra JM (2005) Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 25:485–512PubMed

46.

Kalupahana NS, Massiera F, Quignard-Boulange A, Ailhaud G, Voy BH, Wasserman DH, Moustaid-Moussa N (2012) Overproduction of angiotensinogen from adipose tissue induces adipose inflammation, glucose intolerance, and insulin resistance. Obesity 20:48–56PubMed

47.

Massiera F, Seydoux J, Geloen A, Quignard-Boulange A, Turban S, Saint-Marc P, Fukamizu A, Negrel R, Ailhaud G, Teboul M (2001) Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 142:5220–5225PubMed

48.

Zhou MS, Schulman IH, Zeng Q (2012) Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease. Vasc Med 17:330–341. https://doi.org/10.1177/1358863X12450094CrossRefPubMed

49.

Simões e Silva AC, Miranda AS, Rocha NP, Teixeira AL (2017) Renin angiotensin system in liver diseases: friend or foe? World J Gastroenterol 23:3396–3406PubMedPubMedCentral

50.

Vilas-Boas WW, Ribeiro-Oliveira A, Pereira RM, Ribeiro CR, Almeida J, Nadu AP, Simões e Silva AC, Santos RA (2009) Relationship between angiotensin-(1-7) and angiotensin II correlates with hemodynamic changes in human liver cirrhosis. World J Gastroenterol 15:2512–2519PubMedPubMedCentral

51.

Pereira RM, Santos RA, Teixeira MM, Leite VH, Costa LP, Costa Dias FL, Barcelos LS, Collares GB, Simões e Silva AC (2007) The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of angiotensin-(1-7). J Hepatol 46:674–681PubMed

52.

Herath CB, Warner FJ, Lubel JS, Dean RG, Jia Z, Lew RA, Smith AI, Burrell LM, Angus PW (2007) Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J Hepatol 47:387–395PubMedPubMedCentral

53.

Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, Liu FF, Zhang K, Zhang C (2014) Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol 11:413–426PubMedPubMedCentral

54.

Domenig O, Manzel A, Grobe N, Konigshausen E, Kaltenecker CC, Kovarik JJ, Stegbauer J, Gurley SB, van Oyen D, Antlanger M, Bader M, Motta-Santos D, Santos RA, Elased KM, Saemann MD, Linker RA, Poglitsch M (2016) Neprilysin is a mediator of alternative renin-angiotensin-system activation in the murine and human kidney. Sci Rep 6:33678PubMedPubMedCentral

55.

Westwood BM, Chappell MC (2012) Divergent pathways for the angiotensin-(1-12) metabolism in the rat circulation and kidney. Peptides 35:190–195PubMedPubMedCentral

56.

Myohanen TT, Garcia-Horsman JA, Tenorio-Laranga J, Mannisto PT (2009) Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J Histochem Cytochem 57:831–848PubMedPubMedCentral

57.

Munoz MC, Giani JF, Dominici FP (2010) Angiotensin-(1-7) stimulates the phosphorylation of Akt in rat extracardiac tissues in vivo via receptor Mas. Regul Pept 161:1–7. https://doi.org/10.1016/j.regpep.2010.02.001CrossRefPubMed

58.

Zohn IE, Symons M, Chrzanowska-Wodnicka M, Westwick JK, Der CJ (1998) Mas oncogene signaling and transformation require the small GTP-binding protein Rac. Mol Cell Biol 18:1225–1235PubMedPubMedCentral

59.

Alenina N, Bader M, Walther T (2002) Imprinting of the murine MAS protooncogene is restricted to its antisense RNA. Biochem Biophys Res Commun 290:1072–1078PubMed

60.

Santos SHS (2019) Angiotensin-(1-7): role in the endocrine system. In: Santos RAS (ed) Angiotensin-(1-7): a comprehensive review. Springer International Publishing, pp 153–168

61.

Simões e Silva AC, Santos RA (2019) Kidney. In: Santos RA (ed) Angiotensin-(1-7): a comprehensive review. Springer International Publishing, Cham, pp 117–130

62.

Vijayaraghavan K, Deedwania P (2011) Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention. Cardiol Clin 29:137–156PubMed

63.

Ferreira AJ, Castro CH, Santos RA (2019) Heart–coronary vessels and cardiomyocytes. In: Santos RAS (ed) Angiotensin-(1-7): a comprehensive review. Springer International Publishing, pp 73–81

64.

Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, Venugopal CS, Francis J, Reudelhuber T, Santos RA, Patel JM, Raizada MK, Katovich MJ (2010) The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182:1065–1072PubMedPubMedCentral

65.

Magalhaes GS, Barroso LC, Reis AC, Rodrigues-Machado MG, Gregorio JF, Motta-Santos D, Oliveira AC, Perez DA, Barcelos LS, Teixeira MM, Santos RA, Pinho V, Campagnole-Santos MJ (2018) Angiotensin-(1-7) promotes resolution of eosinophilic inflammation in an experimental model of asthma. Front Immunol 9:58PubMedPubMedCentral

66.

Guimaraes PS, Santiago NM, Xavier CH, Velloso EP, Fontes MA, Santos RA, Campagnole-Santos MJ (2012) Chronic infusion of angiotensin-(1-7) into the lateral ventricle of the brain attenuates hypertension in DOCA-salt rats. Am J Physiol Heart Circ Physiol 303:H393–H400PubMed

67.

Campagnole-Santos MJ, Gironacci MM, Fontes MA (2019) Brain. In: Santos RA (ed) Angiotensin-(1-7): a comprehensive review. Springer International Publishing, Cham, pp 55–71

68.

Guimaraes PS, Oliveira MF, Braga JF, Nadu AP, Schreihofer A, Santos RA, Campagnole-Santos MJ (2014) Increasing angiotensin-(1–7) levels in the brain attenuates metabolic syndrome-related risks in fructose-fed rats. Hypertension 63:1078–1085PubMed

69.

Mecca AP, Regenhardt RW, O'Connor TE, Joseph JP, Raizada MK, Katovich MJ, Sumners C (2011) Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol 96:1084–1096PubMedPubMedCentral

70.

Santos SH, Fernandes LR, Mario EG, Ferreira AV, Porto LC, Alvarez-Leite JI, Botion LM, Bader M, Alenina N, Santos RA (2008) Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57:340–347PubMed

71.

Schön M, Kovaničová Z, Košutzká Z, Nemec M, Tomková M, Jacková L, Máderová D, Slobodová L, Valkovič P, Ukropec J (2019) Effects of running on adiponectin, insulin and cytokines in cerebrospinal fluid in healthy young individuals. Sci Rep 9:1–11

72.

Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A, Soares E, Barbosa C, Kjeldsen F, Oliveira A, Braga J, Savergnini S, Maia G, Peluso AB, Passos-Silva D, Ferreira A, Alves F, Martins A, Raizada M, Paula R, Motta-Santos D, Klempin F, Pimenta A, Alenina N, Sinisterra R, Bader M, Campagnole-Santos MJ, Santos RA (2013) Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 112:1104–1111PubMed

73.

Annweiler C, Cao Z, Wu Y, Faucon E, Mouhat S, Kovacic H, Sabatier J-M (2020) Counter-regulatory ‘renin-angiotensin’ system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients. Curr Drug Targets – Infect Disord. https://doi.org/10.2174/1871526520666200518073329

74.

Schleifenbaum J (2019) Alamandine and its receptor MrgD pair up to join the protective arm of the renin-angiotensin system. Front Med 6:107

75.

Jesus ICG, Scalzo S, Alves F, Marques K, Rocha-Resende C, Bader M, Santos RA, Guatimosim S (2018) Alamandine acts via MrgD to induce AMPK/NO activation against ANG II hypertrophy in cardiomyocytes. Am J Phys Cell Phys 314:C702–C711

76.

Yugandhar VG, Clark MA (2013) Angiotensin III: a physiological relevant peptide of the renin angiotensin system. Peptides 46:26–32PubMed

77.

Park BM, Cha SA, Lee SH, Kim SH (2016) Angiotensin IV protects cardiac reperfusion injury by inhibiting apoptosis and inflammation via AT4R in rats. Peptides 79:66–74PubMed

78.

Martínez-Martos JM, del Pilar Carrera-González M, Dueñas B, Mayas MD, García MJ, Ramírez-Expósito MJ (2011) Renin angiotensin system-regulating aminopeptidase activities in serum of pre- and postmenopausal women with breast cancer. Breast 20:444–447PubMed

79.

Padia SH, Howell NL, Siragy HM, Carey RM (2006) Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat. Hypertension 47:537–544PubMed

80.

Wright JW, Krebs LT, Stobb JW, Harding JW (1995) The angiotensin IV system: functional implications. Front Neuroendocrinol 16:23–52PubMed

81.

Lochard N, Thibault G, Silversides DW, Touyz RM, Reudelhuber TL (2004) Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist. Circ Res 94:1451–1457PubMed

82.

Vinh A, Widdop RE, Drummond GR, Gaspari TA (2008) Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovasc Res 77:178–187PubMed

83.

Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY (2001) Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 276:48623–48626PubMed

84.

Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM (2004) Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383:45–51PubMedPubMedCentral

85.

Ocaranza MP, Moya J, Barrientos V, Alzamora R, Hevia D, Morales C, Pinto M, Escudero N, Garcia L, Novoa U, Ayala P, Diaz-Araya G, Godoy I, Chiong M, Lavandero S, Jalil JE, Michea L (2014) Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. J Hypertens 32:771–783PubMed

86.

Sotomayor-Flores C, Rivera-Mejias P, Vasquez-Trincado C, Lopez-Crisosto C, Morales PE, Pennanen C, Polakovicova I, Aliaga-Tobar V, Garcia L, Roa JC, Rothermel BA, Maracaja-Coutinho V, Ho-Xuan H, Meister G, Chiong M, Ocaranza MP, Corvalan AH, Parra V, Lavandero S (2020) Angiotensin-(1-9) prevents cardiomyocyte hypertrophy by controlling mitochondrial dynamics via miR-129-3p/PKIA pathway. Cell Death Differ. https://doi.org/10.1038/s41418-020-0522-3

87.

Cha SA, Park BM, Kim SH (2018) Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor. Korean J Physiol Pharmacol 22:447–456PubMedPubMedCentral

88.

Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K (2006) Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 350:1026–1031PubMed

89.

Ahmad S, Varagic J, Groban L, Dell’Italia LJ, Nagata S, Kon ND, Ferrario CM (2014) Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep 16:429PubMedPubMedCentral

90.

Jankowski V, Vanholder R, van der Giet M, Tolle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J (2007) Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 27:297–302PubMed

91.

Hrenak J, Paulis L, Simko F (2016) Angiotensin A/alamandine/MrgD axis: another clue to understanding cardiovascular pathophysiology. Int J Mol Sci 17:1098PubMedCentral

92.

Simões e Silva AC, Diniz JS, Regueira Filho A, Santos RA (2004) The renin angiotensin system in childhood hypertension: selective increase of angiotensin-(1-7) in essential hypertension. J Pediatr 145:93–98PubMed

93.

Flynn J (2013) The changing face of pediatric hypertension in the era of the childhood obesity epidemic. Pediatr Nephrol 28:1059–1066PubMed

94.

South AM, Nixon PA, Chappell MC, Diz DI, Russell GB, Shaltout HA, O’Shea TM, Washburn LK (2019) Obesity is associated with higher blood pressure and higher levels of angiotensin II but lower angiotensin-(1-7) in adolescents born preterm. J Pediatr 205:55–60PubMed

95.

Khatri M, Zitovsky J, Lee D, Nayyar K, Fazzari M, Grant C (2020) The association between serum chloride levels and chronic kidney disease progression: a cohort study. BMC Nephrol 21:165PubMedPubMedCentral

96.

Burnier M (2020) Increasing potassium intake to prevent kidney damage: a new population strategy? Kidney Int 98:59–61PubMed

97.

South AM, Shaltout HA, Washburn LK, Hendricks AS, Diz DI, Chappell MC (2019) Fetal programming and the angiotensin-(1-7) axis: a review of the experimental and clinical data. Clin Sci 133:55–74

98.

Pinheiro SV, Ferreira AJ, Kitten GT, Silveira KD, da Silva DA, Santos SH, Gava E, Castro CH, Magalhaes JA, da Mota RK, Botelho-Santos GA, Bader M, Alenina N, Santos RA, Simões e Silva AC (2009) Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 75:1184–1193PubMed

99.

Silveira KD, Barroso LC, Vieira AT, Cisalpino D, Lima CX, Bader M, Arantes RM, Santos RA, Simões e Silva AC, Teixeira MM (2013) Beneficial effects of the activation of the angiotensin-(1-7) MAS receptor in a murine model of adriamycin-induced nephropathy. PLoS One 8:e66082PubMedPubMedCentral

100.

Silva-Filha R, Pinheiro SV, Cordeiro TM, Feracin V, Vieira EL, Miranda AS, Simões e Silva AC (2019) Evidence for a role of angiotensin converting enzyme 2 in proteinuria of idiopathic nephrotic syndrome. Biosci Rep 39:BSR20181361

101.

Nadarajah R, Milagres R, Dilauro M, Gutsol A, Xiao F, Zimpelmann J, Kennedy C, Wysocki J, Batlle D, Burns KD (2012) Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 82:292–303PubMedPubMedCentral

102.

Ng HY, Yisireyili M, Saito S, Lee CT, Adelibieke Y, Nishijima F, Niwa T (2014) Indoxyl sulfate downregulates expression of Mas receptor via OAT3/AhR/Stat3 pathway in proximal tubular cells. PLoS One 9:e91517PubMedPubMedCentral

103.

Baum M (2010) Role of the kidney in the prenatal and early postnatal programming of hypertension. Am J Physiol Ren Physiol 298:F235–F247

104.

Zhu Y, Zuo N, Li B, Xiong Y, Chen H, He H, Sun Z, Hu S, Cheng H, Ao Y, Wang H (2018) The expressional disorder of the renal RAS mediates nephrotic syndrome of male rat offspring induced by prenatal ethanol exposure. Toxicology 400:9–19PubMed

105.

Simões e Silva AC, Valerio FC, Vasconcelos MA, Miranda DM, Oliveira EA (2013) Interactions between cytokines, congenital anomalies of kidney and urinary tract and chronic kidney disease. Clin Dev Immunol 2013:597920PubMedPubMedCentral

106.

Rocha NP, Bastos FM, Vieira ELM, Prestes TRR, Silveira KDD, Teixeira MM, Simões SAC (2019) The protective arm of the renin-angiotensin system may counteract the intense inflammatory process in fetuses with posterior urethral valves. J Pediatr 95:328–333

107.

Flynn JT, Mitsnefes M, Pierce C, Cole SR, Parekh RS, Furth SL, Warady BA (2008) Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 52:631–637PubMed

108.

Shatat IF, Flynn JT (2005) Hypertension in children with chronic kidney disease. Adv Chronic Kidney Dis 12:378–384PubMed

109.

Simões e Silva AC, Diniz JC, Pereira RM, Pinheiro SV, Santos RA (2006) Circulating renin angiotensin system in childhood chronic renal failure: marked increase of angiotensin-(1-7) in end-stage renal disease. Pediatr Res 60:734–739PubMed

110.

Sun CY, Chang SC, Wu MS (2012) Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One 7:e34026PubMedPubMedCentral

111.

Liu WC, Tomino Y, Lu KC (2018) impacts of indoxyl sulfate and p-cresol sulfate on chronic kidney disease and mitigating effects of ast-120. Toxins (Basel) 10:367

112.

Ma L, Han C, Peng T, Li N, Zhang B, Zhen X, Yang X (2016) Ang-(1-7) inhibited mitochondrial fission in high-glucose-induced podocytes by upregulation of miR-30a and downregulation of Drp1 and p53. J Chin Med Assoc 79:597–604PubMed

113.

Ali Q, Patel S, Hussain T (2015) Angiotensin AT2 receptor agonist prevents salt-sensitive hypertension in obese Zucker rats. Am J Physiol Ren Physiol 308:F1379–F1385

114.

Basile DP, Anderson MD, Sutton TA (2011) Pathophysiology of acute kidney injury. Compr Physiol 2:1303–1353

115.

Barroso LC, Silveira KD, Lima CX, Borges V, Bader M, Rachid M, Santos RAS, Souza DG, Simões E, Silva AC, Teixeira MM (2012) Renoprotective effects of AVE0991, a nonpeptide Mas receptor agonist, in experimental acute renal injury. Int J Hypertens 2012:808726PubMedPubMedCentral

116.

Ribeiro-Oliveira A Jr, Nogueira AI, Pereira RM, Boas WWV, dos Santos RAS, Simões e Silva AC (2008) The renin–angiotensin system and diabetes: an update. Vasc Health Risk Manag 4:787–803PubMedPubMedCentral

117.

Alves MT, Chaves ACS, Almeida APM, Simões E, Silva AC, Araújo SA, Mota APL, Dos Mares-Guia TR, Fernandes AP, Gomes KB (2020) Anti-inflammatory effects of C-peptide on kidney of type 1 diabetes mellitus animal model. Mol Biol Rep 47:721–726PubMed

118.

Bangalore S, Fakheri R, Toklu B, Messerli FH (2016) Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ 352:i438PubMedPubMedCentral

119.

Mori J, Patel VB, Ramprasath T, Alrob OA, DesAulniers J, Scholey JW, Lopaschuk GD, Oudit GY (2014) Angiotensin 1–7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Ren Physiol 306:F812–F821

120.

Belisário AR, da Silva AA, Silva CV, de Souza LM, Wakabayashi EA, Araujo SA, Simões e Silva AC (2019) Sickle cell disease nephropathy: an update on risk factors and potential biomarkers in pediatric patients. Biomark Med 13:965–985

121.

Belisário AR, Vieira ELM, Almeida JA, Mendes FG, Miranda AS, Rezende PV, Viana MB, Simões E, Silva AC (2020) Evidence for interactions between inflammatory markers and renin-angiotensin system molecules in the occurrence of albuminuria in children with sickle cell anemia. Cytokine 125:154800PubMed

122.

Belisário AR, Almeida JA, Mendes FG, da Silva DMM, Planes W, Rezende PV, Silva CM, Brito AC, Sales RR, Viana MB, Simões E, Silva AC (2020) Prevalence and risk factors for albuminuria and glomerular hyperfiltration in a large cohort of children with sickle cell anemia. Am J Hematol 95:E125–E128PubMed

123.

Belisário AR, Vieira ÉLM, de Almeida JA, Mendes FG, Miranda AS, Rezende PV, Viana MB, Simões E, Silva AC (2019) Low urinary levels of angiotensin-converting enzyme 2 may contribute to albuminuria in children with sickle cell anaemia. Brit J Hematol 185:190–193

124.

Pinheiro SVB, Dias RF, Fabiano RCG, Araujo SA, Simões e Silva AC (2019) Pediatric lupus nephritis. Braz J Nephrol 41:252–265

125.

Teplitsky V, Shoenfeld Y, Tanay A (2006) The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans. Lupus 15:319–325PubMed

126.

De Albuquerque DA, Saxena V, Adams DE, Boivin GP, Brunner HI, Witte DP, Singh RR (2004) An ACE inhibitor reduces Th2 cytokines and TGF-β1 and TGF-β2 isoforms in murine lupus nephritis. Kidney Int 65:846–859PubMedPubMedCentral

127.

Zhou P, Yang XL, Wang X, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579:270–273PubMedPubMedCentral

128.

South AM, Brady TM, Flynn JT (2020) ACE2, COVID-19, and ACE inhibitor and ARB use during the pandemic: the pediatric perspective. Hypertension 76:16–22PubMed

129.

Epidemiology Working Group of NCIP Epidemic Response, Chinese Center for Disease Control and Prevention (2020) The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 41:145–151

130.

Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, Chen L, Liang L, Zhou J, You L, Wu P, Zhang B, Lu Y, Xia L, Huang L, Yang Y, Liu F, Semple MG, Cowling BJ, Lan K, Sun Z, Yu H, Liu Y (2020) Detection of Covid-19 in children in early January 2020 in Wuhan, China. N Engl J Med 382:1370–1371PubMedPubMedCentral

131.

Task force COVID-19 del Dipartimento Malattie Infettive e Servizio di Informatica, Instituto Superiore di Sanita (2020) Epidemia COVID-19. Aggiornamento Nazionale: 23 aprile 2020 Report, Available from https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_23-aprile-2020.pdf. Accessed 04 June 2020

132.

Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323:1239–1242PubMed

133.

(2020) Coronavirus Disease 2019 in Children – United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Report 69:422–426. https://doi.org/10.15585/mmwr.mm6914e4

134.

Heinonen S, Rodriguez-Fernandez R, Diaz A, Rodriguez-Pastor SO, Ramilo O, Mejias A (2019) Infant immune response to respiratory viral infections. Immunol Allergy Clin 39:361–376

135.

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q (2020) Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367:1444–1448PubMedPubMedCentral

136.

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-Paredes C, Henao-Martinez AF, Paniz-Mondolfi A, Lagos-Grisales GJ, Ramírez-Vallejo E, Suárez JA, Zambrano LI, Villamil-Gómez WE, Balbin-Ramon GJ, Rabaan AA, Harapan H, Dhama K, Nishiura H, Kataoka H, Ahmad T, Sah R, Latin American Network of Coronavirus Disease 2019-COVID-19 Research (LANCOVID-19) (2020) Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis. Travel Med Infec Dis 34:101623

137.

Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D (2020) COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Resp Critic Care Med 201:1299–1300

138.

Pedersen SF, Ho YC (2020) SARS-CoV-2: a storm is raging. J Clin Invest 130:2202–2205PubMedPubMedCentral

139.

Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39:529–539PubMedPubMedCentral

140.

Vinturache AE, Smith FG (2014) Do angiotensin type 2 receptors modulate haemodynamic effects of type 1 receptors in conscious newborn lambs? J Renin Angiotensin Aldosterone Syst 15:450–457PubMed

141.

Sampson AK, Moritz KM, Denton KM (2012) Postnatal ontogeny of angiotensin receptors and ACE2 in male and female rats. Gender Med 9:21–32

142.

Bunyavanich S, Do A, Vicencio A (2020) Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 323:2427–2429. https://doi.org/10.1001/jama.2020.8707CrossRefPubMedPubMedCentral

143.

Silva-Antonialli MM, Tostes RC, Fernandes L, Fior-Chadi DR, Akamine EH, Carvalho MHC, Nigro D (2004) A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats. Cardiovasc Res 62:587–593PubMed

144.

Hinojosa-Laborde C, Craig T, Zheng W, Ji H, Haywood JR, Sandberg K (2004) Ovariectomy augments hypertension in aging female Dahl salt-sensitive rats. Hypertension 44:405–409PubMed

145.

Sullivan JC, Rodriguez-Miguelez P, Zimmerman MA, Harris RA (2015) Differences in angiotensin (1–7) between men and women. Am J Physiol Heart Circ Physiol 308:H1171–H1176PubMedPubMedCentral

Title: 2020 update on the renin–angiotensin–aldosterone system in pediatric kidney disease and its interactions with coronavirus
Authors: Ana Cristina Simões e Silva
Katharina Lanza
Vitória Andrade Palmeira
Larissa Braga Costa
Joseph T. Flynn
Publication date: 01-06-2021
Publisher: Springer Berlin Heidelberg
Keywords: Coronavirus
COVID-19
Hypertension
Chronic Kidney Disease
Hypertension
Published in: Pediatric Nephrology / Issue 6/2021
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-020-04759-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

2020 update on the renin–angiotensin–aldosterone system in pediatric kidney disease and its interactions with coronavirus

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2021

Rocky road—an uncommon reason for kidney allograft dysfunction: Answers

Neutrophil gelatinase-associated lipocalin for urinary tract infection and pyelonephritis: a systematic review

Calcineurin inhibitors in nephrotic syndrome secondary to podocyte gene mutations: a systematic review

Renal tumors in tuberous sclerosis complex

Pediatric atypical hemolytic–uremic syndrome due to auto-antibodies against factor H: is there an interest to combine eculizumab and mycophenolate mofetil?

Treatment strategy for Streptococcus pneumoniae-associated hemolytic uremic syndrome